Rosacea Botox isn't forehead Botox, and your consent should say so.

"It's just Botox" is the wrong thing to hear before this injection

You're in the chair, cheeks hot and blotchy from the drive over, and the person holding the syringe offers the line meant to settle you: it's just Botox. The vial might hold the same product that smooths forehead lines. Very little else about what happens next matches.

For rosacea flushing, the toxin is usually diluted and placed into the skin itself, in a grid of shallow injections across the cheeks (often called intradermal or micro-dosed botulinum toxin). The target is different. The dosing isn't standardized. And the evidence base is a short shelf of small studies, nowhere near the decades of cosmetic trials that make a forehead appointment feel routine.

"Just Botox" borrows the track record of one procedure to reassure you about another.

The Borrowed-Label Problem

We call it the Borrowed-Label Problem: a treatment that works on nerves and blood vessels gets sold, priced and consented to under a cosmetic label.

Botulinum toxin stops nerve endings from releasing acetylcholine, the chemical messenger nerves use to trigger a response. In a frown line, that response is a muscle contracting, so the line softens. In rosacea skin, the proposed targets sit elsewhere: the nerve signals that open small blood vessels during a flush, and mast cells, immune cells that release inflammatory chemicals when provoked. Choi et al. 2019 reported botulinum toxin blocking mast-cell degranulation (the release of those chemicals) in a mouse model of rosacea Choi JE, Di Nardo A et al., 'Botulinum toxin blocks mast cells and prevents rosacea like inflammation,' Journal of Dermatological Science, 2019, found onabotulinum toxin inhibits mast cell degranulation in a rosacea mouse model. ([source](https://pubmed.ncbi.nlm.nih.gov/30658871/)).

That fits how dermatology now describes the condition. The National Rosacea Society's 2017 expert update (Gallo et al., JAAD 2018) dropped fixed subtypes in favor of phenotypes, meaning individual features like flushing, persistent redness and bumps, and it points to the nervous system and blood vessels as part of what drives the disease.

Flushing is a nerve-and-vessel event. So is the injection aimed at it.

Why neither "tweakment" nor "guesswork" fits

Two framings dominate. Med-spa marketing treats rosacea injections as an add-on, booked alongside lip filler. Skeptics wave the whole thing off as off-label guesswork. Both miss where the evidence actually sits.

It has moved past single anecdotes. Small controlled studies exist, and they lean the same way on redness and flushing. But nobody can yet promise a result, name a standard dose, or tell you how a fourth round compares to the first.

No botulinum toxin product is FDA-approved for rosacea. The FDA-approved Botox label lists indications only for strabismus and blepharospasm/dystonia-associated conditions, not rosacea ([source](https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103000s5232lbl.pdf)), so every rosacea injection is off-label. That's common and legal in dermatology. It also means the dose, dilution and injection map come from the injector's reading of the literature rather than a label.

The risks are specific to this pattern, too. Toxin in the cheek can drift toward the muscles around the mouth, and temporary smile asymmetry has been reported as a known but uncommon side effect. A forehead consent form doesn't prepare anyone for that.

What the rosacea Botox studies actually show

The published record is small and short. Early reports were open-label case series, meaning everyone got the injection and nobody got a placebo. Later work added split-face and placebo-controlled designs. Sample sizes stayed in the tens.

Most studies rated redness with a clinician scale or standardized photographs Outcomes were measured with validated scales such as the Clinician Erythema Assessment scale, erythema index, or polarized photography ([source](https://pmc.ncbi.nlm.nih.gov/articles/PMC8021409/)) and followed people for weeks to a few months. Effects appear to fade within about that window Botulinum toxin A effects for rosacea erythema/flushing generally last 3–6 months across studies before symptoms recur ([source](https://pmc.ncbi.nlm.nih.gov/articles/PMC9515256/)), so repeat treatment is the working assumption.

The gaps matter as much as the findings. Evidence on papules and pustules (the acne-like bumps some people with rosacea get) is thin. Repeated cheek injections over years haven't been studied at scale. And published trials rarely break results out by skin tone A rosacea facial cream trial enrolled Chinese women with Fitzpatrick skin types III-IV specifically ([source](https://clinicaltrials.gov/study/NCT07637032)).

How one round of injections gets misjudged

Picture a common timeline. Someone flushes most days through a hot summer, gets injected in early autumn, and comes back for review a few weeks later. Their cheeks look calmer. The injector sees improvement. So do they.

Now count the confounders. Autumn brings cooler air, and heat sits near the top of the triggers patients report (NRS patient survey National Rosacea Society survey of 1,066 rosacea sufferers identified triggers including sun exposure, hot weather, and alcohol ([source](https://pmc.ncbi.nlm.nih.gov/articles/PMC8794493/))). Maybe they quit wine after the last bad flare. Maybe a new topical started the same month. The follow-up captures one day, under one light, after however long in a waiting room.

Nobody in that story is being dishonest. Memory just compares the worst flares against one good afternoon.

When the effect wears off months later, the same trap runs in reverse. Is the redness creeping back, or is it the first cold snap and a space heater under the desk? Without a record, the decision to pay for another round rests on a feeling.

What changes if you treat it as a nerve-and-vessel procedure

The appointment looks different before a needle comes out.

Ask whether the plan is intradermal or intramuscular, and what dose and dilution the injector uses and why. Ask which of your features they expect to change: flushing, persistent redness, burning, bumps. Ask how they keep toxin away from the muscles around the mouth, and what happens if your smile shifts. Ask how long results lasted in the studies they rely on, and what a second round costs.

Then hold the result to the standard you'd use for any other medical treatment: a measured baseline, a defined outcome, a comparison over time. A temporary effect with a real price needs better proof than "it looks better today." The question is whether flushing went from most days to some days, and whether that held.

The log is the only lab test you get

There's no blood test for flushing. The measurement is you, over weeks.

A useful log starts a few weeks before any injection, so the baseline includes ordinary bad days. Each flush gets a rough severity, the context (heat, a hot drink, alcohol, stress, exercise) and how it felt. Photos happen under similar light at a similar time of day. And the log keeps running through the months after, exactly when memory is least reliable.

Sensation counts as much as color. On darker skin, redness can be harder to see in person and in photos while burning, stinging and heat are fully present (Alexis et al., JAAD 2019 Facial erythema and telangiectasia are more difficult to visualize/appreciate in patients with skin of color. ([source](https://jcadonline.com/diagnosing-treating-rosacea-skin-of-color/))). A log built only on how red a photo looks will undercount flushing for a lot of people.

Skinframe is built around this kind of record: flush episodes, triggers, sensations and consistent photos, ready to bring to an appointment Skinframe stores all photos and severity history on-device (SwiftData with a private CloudKit backup, not a company-run server), and lets users export their own data at any time as a CSV file or as a doctor-ready PDF summary.. We won't tell you whether to get injected. Talk to your dermatologist before starting, and bring the log to the follow-up.

What we're watching next

Three things would move this picture. Larger randomized trials with placebo arms and follow-up past the first few months. Head-to-head comparisons against the topicals dermatologists already prescribe for persistent redness, like brimonidine and oxymetazoline. And safety data on people treated repeatedly over years, since that's how this gets used once someone decides it works.

Until then, rosacea Botox sits where the small trials put it: promising for flushing and redness, unproven for the rest, and best judged by your own numbers rather than a sales pitch.